Please assess the completion status of the following clinical trial:

Trial Title: Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* New York Heart Association (NYHA) Class III or IV CHF refractory to maximal medical therapy (ACE inhibitor, B-blocker, digoxin and diuretics, resynchronization therapy or Implantable Cardioverter Defibrillator when applicable) and/or conventional surgery.~* Inoperable coronary artery disease with intractable anginal symptoms~* Malignant ventricular arrhythmias unresponsive to medical or surgical therapy~* 18-65 years of age~* Obtained agreement for participation from the transplant cardiology team~* No evident contraindication to liver transplantation other than the underlying cardiac disorder~* Able to travel to the University of Pennsylvania for routine post-transplant visits and study visits for a minimum of 6 months after transplantation~* No active illicit substance abuse~* Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant due to the increased risk of birth defects and/or miscarriage~* Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HCV transmission~* Inclusion criteria for treatment (not for entry as study patient) will include any detectable HCV RNA by week 4 post-heart transplantation~* Able to provide informed consent~Exclusion Criteria:~* Hepatocellular carcinoma~* HIV positive~* HCV antibody positive and/or RNA positive~* Hepatitis B surface antigen, core antibody, and/or DNA positive~* Any other chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD) with abnormal liver enzymes~* Persistently elevated liver transaminases~* Congenital heart disease~* Fibrosis by liver biopsy or total bilirubin \> 2.5 with associated evidence of synthetic dysfunction.~* Pregnant or nursing (lactating) women~* Known allergy or intolerance to tacrolimus that would require post-transplant administration of cyclosporine, rather than tacrolimus given the drug-drug interaction between cyclosporine and ZEPATIER~* Waitlisted for a multi-organ transplant~* Evidence of end organ damage due to diabetes (e.g. retinopathy, nephropathy, ulcerations) and /or brittle diabetes mellitus (e.g. history of diabetic ketoacidosis) and/or uncontrolled diabetes as evidence by a HgbA1C of 7.5-8.5.~* Chronic bronchitis, chronic obstructive pulmonary disease, inability to stop smoking.~* Hematologic: Significant coagulation abnormalities, bleeding diatheses.~* Psychosocial: Profound neurocognitive impairment with absence of social support.~* Active mental illness or psychosocial instability~* Inadequate insurance or financial support for post-transplant care.~* Evidence of drug, tobacco or alcohol abuse within the past six months and completion of recommended therapy/services or meets satisfied parameters as indicated by social work staff and/or consult team.~* History of chronic non-compliance.~* Amyloidosis (restricted to cardiac only, without evidence of extra cardiac involvement)~* BMI ≥38~* Active peptic ulcer disease.~* Severe malnutrition.~* Major chronic disabling illness (e.g. lupus, severe arthritis, neurologic diseases, previous stroke with profound residual).~* Pulmonary infarction within the past 6 weeks~* Severe pulmonary hypertension as evidenced by a fixed pulmonary vascular resistance of greater than 4 Wood units on appropriate medical therapy.~* Patient refusal to receive blood products or transfusions during heart transplant surgery.~* Severe chronic obstructive pulmonary disease~* Current clinical sepsis.~* Symptomatic or severe vascular disease.~* Chronic Kidney Disease Stage IV, Glomerular Filtration Rate \< 30~* History of Mantle radiation.~* Asymptomatic renal cell carcinoma \<1 year from curative treatment.~* Symptomatic renal cell carcinoma \<5 years from curative treatment.~* Prostate cancer \<2 years from curative treatment.~* Uterine or cervical cancer \<2 years from curative treatment.~* Any other cancer other than the above including malignant melanoma, \< 5 years from treatment apart from other skin malignancies.~Donor Organ Selection Criteria:~General criteria (although there can be exceptions on a case-by-case basis)~* Detectable HCV RNA~* Genotype 1 or 4 HCV~* Age \<=55 years~* No history of coronary artery disease~* No congenital heart disease except a repaired atrial septal defect (ASD) provided the patient has normal right ventricular function~* No history of arrhythmia (atrial fibrilation, atrial flutter or VT) except during resuscitation from fatal event.~* No evidence of cirrhosis~Echocardiographic criteria:~* Left ventricular ejection fraction (LVEF) \>=50%~* Normal right ventricular function~* No left ventricular hypertrophy (LVH) - septal wall thickness \<1 cm~* No left ventricular hypertrophy (LVH)- posterior wall thickness \<1 cm~* No significant valvular heart disease - more than mild tricuspid regurgitation, more than mild mitral regurgitation, more than trace aortic regurgitation. No mitral or aortic stenosis.~* No congenital heart disease - transposition of the great vessels, ventricular septal defect (VSD), ASD, and/or single ventricle (Fontan)~Right heart catheterization criteria:~* Right atrial pressure \<=10mmHg~* Pulmonary capillary wedge pressure \<=18mmHg~* CI \>=2.1 l/min/m2~* Pulmonary hypertension is allowed if the patient has normal right ventricular function and a normal tricuspid valve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zepatier (grazoprevir 100mg and elbasvir 50 mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).